Global Partners LP
Recent
price
P/E
ratio
div
yld
7.87%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Global Partners LP Global Partners LP (NYSE: GLP), a master limited partnership founded in 2005 with roots tracing back to 1933, serves as a leading midstream logistics and marketing company headquartered in Waltham, Massachusetts. The company engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates including diesel and heating oil, residual oil, renewable fuels such as biodiesel and ethanol, crude oil, propane, natural gas, and bunker fuel to wholesalers, retailers, gasoline station operators, sub-jobbers, commercial and industrial end-users, and public sector customers; it operates through three segments—Wholesale, which supplies branded and unbranded gasoline, home heating oil, kerosene, and residual oil via railcars, barges, trucks, and pipelines; Gasoline Distribution and Station Operations (GDSO), which distributes fuels to over 1,700 owned, leased, or supplied retail locations featuring convenience stores, prepared foods, car washes, lottery, and ATM services primarily across Northeast states, the Mid-Atlantic, and Texas; and Commercial, which delivers custom-blended fuels and energy products with a focus on the Northeast U.S. Global maintains dedicated storage at 54 liquid energy terminals connected to rail, pipeline, and marine assets spanning from Maine to Florida and into the U.S. Gulf States, while offering low-carbon solutions like GlobalGLO to support carbon footprint reduction. In recent developments, Global Partners LP completed the acquisition of a 959,730-barrel liquid energy terminal in East Providence, Rhode Island, from ExxonMobil Oil Corporation in November 2024, enhancing gasoline infrastructure, truck rack capacity, and supply optionality for its Northeast retail and marketing operations while adding surplus real estate for future development; the company also issued $450 million in senior unsecured notes due 2033 in June 2025, co-issued with GLP Finance Corp. and guaranteed by subsidiaries, to bolster its capital structure amid ongoing terminal expansions and diversification into renewable fuels.
Company News
The Precision Peptide Company Locks In Exclusive Manufacturing Rights Across Its Needle-Free Line
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market
Global Partners (GLP) is an Incredible Growth Stock: 3 Reasons Why
Are Investors Undervaluing Global Partners (GLP) Right Now?
Omada Health to Present Peer-Reviewed Research on Improving Weight Loss and Body Composition During GLP-1 Treatment at World Obesity and Weight Management Congress
Hims & Hers Health: The Lollapalooza Effect Of GLP-1s
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
Lexaria Announces Results from Animal Study GLP-1-A26-1
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
New Peptide ETF From REX Looks Beyond GLP-1 Drugs
Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
The Precision Peptide Company Advances Needle-Free GLP-1 Tirzepatide Patch into Formal U.S. Testing
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution
Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology
Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform